

See http://www.insight-group.org/pdf/Insight_CFR_HVP.pdf

09:00 am	Welcome and Introduction: <i>Finlay Macrae, Hans Vasen and Mark Jenkins</i> What is InSiGHT? - <i>Gabriela Moeslein</i> What is the US CFR? – <i>S. Gallinger</i> How does the HVP fit?- <i>Richard Cotton</i> Why should InSiGHT and the CFR exchange and collaborate? - <i>Finlay Macrae</i>
09:20-12:30 md	Plenary session: Project proposals
09:20 am	A: Unclassified variants in MMR genes
09:20	Introduction: Aims of the session – <i>Annika Lindblom</i>
09:25	Report of the IARC meeting on unclassified variants in Lyon (Feb 19-20th, 2009) - <i>Maurizio Genuardi (co-chair and lead), Sean Tavtigian</i>
09:50	Phenotype descriptions for annotation to the variant database - <i>Finlay Macrae (lead), Inge Bernstein</i>
10:50	Functional Assays - <i>R. Hofstra (lead) N. de Winde, M. Nystrom, R. Sijmons</i>
10:30	Proposal for world wide collaborative project focusing on unclassified variants - <i>Annika Lindblom (lead)</i>
11.00 am	Morning tea
11.30 am	B: Databasing including uploading, and responses from InSiGHT/LOVD
11:30	Aims of the session – <i>Mike Woods</i>
11:35	Demonstration of InSiGHT variant database on line – <i>J. den Dunnen (lead), R. Sijmons, M. Woods, P. Peltomaki, H. Vasen, R. Hofstra</i>
12:00	Experience uploading to InSiGHT LOVD database – <i>P. Propping, Ming Qi, B. Bapat</i>
12:15	Privacy and confidentiality - <i>Sue Povey for HVP (TBC)</i>
12:30	National nodes for variant data collection - national LSDBs - how do they work: how does data get in?, who curates? Who has access? What are the confidentiality issues? – <i>(lead: not known yet)</i>
12:50	The HVP perspective – <i>R. Cotton</i>
01.00 pm	Lunch
02.00 pm	Concurrent sessions:
02.00 pm	C. Risk and prognosis of CRC to relatives in Type X and related familial risk pedigree - <i>John Baron, Finlay Macrae, Huw Thomas (leads)</i>
02.00 pm	D. PMS2 BRAF status in cancers occurring in PMS2 carriers – <i>A. Boussioutas (lead)</i> hPMS2 mutations in patients with loss of MLH1, and PMS2 who have no change found in MLH1 (sequencing and MLPA), and who do not have methylation of MLH1 promotor - <i>A Boussioutas (lead)</i>
03.30 pm	Afternoon tea
04.00 pm	E. Modifier genes in MMR gene carriers Candidate studies - <i>R Scott (lead)</i> The Australian GWAS and CNV proposal for modifier genes in MLH1 and MSH2 carriers – <i>G. Hannan (lead)</i> GWAS studies in non-HNPCC, non-FAP familial bowel cancer – <i>I. Tomlinson (lead), G. Hannan, R. Houlston</i>
04.00 pm	F. Surveillance and management in familial colorectal cancer Surveillance outcomes in relatives of probands with MSI-H cancers – <i>D. Ahnen (lead)</i> Segmental or total colectomy? An observational study of outcomes – <i>S. and B. Parry (leads) G. Moeslein</i>
05.00 pm	G. Other studies G1: GWAS studies - <i>Garry Hannan, Malcolm Dunlop, Steve Gallinger, Riki Peters, Steve Gruber, G. Casey, Graham Byrne, I. Tomlinson, R. Houlston</i> G2: The Cancer Genome Analyst study - <i>Daniela Seminara</i>
05.45 pm	Wrap up including Funding: <i>Richard Cotton, Finlay Macrae, Gabriela Moeslein, Steve Gallinger</i>

Program subject to change.

Your attendance is contingent on registering for the day's activities (June 24th); InSiGHT would strongly encourage you to attend the entire meeting, as there is a host of research papers being presented, representing the latest research in familial GI cancer. Special arrangements may apply for the US CFR SC members.

Please email your response to Professor Finlay, Hon Secretary InSiGHT, PO Box 2010 Royal Melbourne Hospital, 3050, Victoria Australia, or fax +61393482004, or email to Finlay.macrae@mh.org.au This e-mail address is being protected from spambots. You need JavaScript enabled to view it Places are limited: Acceptance will be sent to you within a week of your application.

Footnote: InSiGHT encourages and would welcome all attending this meeting and/or interested in familial GI cancer to be members of InSiGHT. Fees are modest (75 pounds sterling or 30 pounds sterling without subscription to Familial Cancer). InSiGHT is a collaborative, multi-disciplinary group incorporating most of the world's expertise in familial GI cancer, especially colorectal cancer. It's members cover basic science including molecular biologists and genetic epidemiologists, through to clinicians, and psycho-social scientists. It focuses on collaborative research, and educates its members through the biennial meetings, its website and Newsletters. Membership application is easy: Go to <http://www.insight-group.org/society/members/registration/>